-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Blackstone Inc. Reduces Stock Holdings in Imago BioSciences, Inc. (NASDAQ:IMGO)
Blackstone Inc. Reduces Stock Holdings in Imago BioSciences, Inc. (NASDAQ:IMGO)
Blackstone Inc. reduced its holdings in Imago BioSciences, Inc. (NASDAQ:IMGO – Get Rating) by 27.8% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,436,732 shares of the company's stock after selling 938,305 shares during the period. Blackstone Inc. owned about 0.07% of Imago BioSciences worth $46,956,000 at the end of the most recent quarter.
Other large investors have also made changes to their positions in the company. Metropolitan Life Insurance Co NY purchased a new position in Imago BioSciences during the first quarter valued at $28,000. Ameritas Investment Partners Inc. lifted its holdings in Imago BioSciences by 108.3% during the first quarter. Ameritas Investment Partners Inc. now owns 1,556 shares of the company's stock valued at $30,000 after purchasing an additional 809 shares in the last quarter. Virtus ETF Advisers LLC purchased a new position in Imago BioSciences during the fourth quarter valued at $215,000. American International Group Inc. lifted its holdings in Imago BioSciences by 92.3% during the first quarter. American International Group Inc. now owns 9,964 shares of the company's stock valued at $192,000 after purchasing an additional 4,782 shares in the last quarter. Finally, MetLife Investment Management LLC purchased a new position in Imago BioSciences during the first quarter valued at $242,000. 99.50% of the stock is owned by hedge funds and other institutional investors.
Get Imago BioSciences alerts:Insider Activity
In related news, insider Jennifer Peppe sold 5,598 shares of the firm's stock in a transaction dated Monday, August 15th. The shares were sold at an average price of $19.41, for a total transaction of $108,657.18. Following the completion of the sale, the insider now directly owns 148,809 shares in the company, valued at $2,888,382.69. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders sold 8,168 shares of company stock worth $155,402 over the last three months. Insiders own 14.90% of the company's stock.
Analyst Ratings Changes
Separately, HC Wainwright decreased their price objective on shares of Imago BioSciences from $36.00 to $35.00 and set a "buy" rating on the stock in a report on Tuesday, August 16th.Imago BioSciences Stock Performance
Shares of NASDAQ IMGO traded up $0.14 during mid-day trading on Friday, reaching $16.91. The company's stock had a trading volume of 86,921 shares, compared to its average volume of 105,353. The stock has a 50-day moving average of $16.38 and a two-hundred day moving average of $17.02. The stock has a market capitalization of $570.54 million, a P/E ratio of -9.50 and a beta of 2.48. Imago BioSciences, Inc. has a 1-year low of $11.56 and a 1-year high of $30.21.
Imago BioSciences Company Profile
(Get Rating)
Imago BioSciences, Inc, a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. Its lead product candidate is bomedemstat, which is in Phase II clinical trials for the treatment of myeloproliferative neoplasms chronic cancers of the bone marrow, such as myelofibrosis, essential thrombocythemia, and polycythemia vera.
See Also
- Get a free copy of the StockNews.com research report on Imago BioSciences (IMGO)
- MarketBeat: Week in Review 9/5 – 9/9
- Prepare For A Record-Setting Quarter For Cyber Security Stocks
- The Auto Market Is Slowly Recovering, These Stocks May Outperform
- Is DocuSign On The Verge Of A Major Reversal?
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
Want to see what other hedge funds are holding IMGO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Imago BioSciences, Inc. (NASDAQ:IMGO – Get Rating).
Receive News & Ratings for Imago BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imago BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.
Blackstone Inc. reduced its holdings in Imago BioSciences, Inc. (NASDAQ:IMGO – Get Rating) by 27.8% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,436,732 shares of the company's stock after selling 938,305 shares during the period. Blackstone Inc. owned about 0.07% of Imago BioSciences worth $46,956,000 at the end of the most recent quarter.
根据黑石最近提交给美国证券交易委员会(美国证券交易委员会)的文件,今年第一季度,黑石集团减持了Imago BioSciences,Inc.(美国证券交易委员会代码:IMGO-GET)27.8%的股份。该基金在此期间出售了938,305股后,持有该公司2,436,732股股票。截至最近一个季度末,黑石集团持有Imago BioSciences约0.07%的股份,价值46,956,000美元。
Other large investors have also made changes to their positions in the company. Metropolitan Life Insurance Co NY purchased a new position in Imago BioSciences during the first quarter valued at $28,000. Ameritas Investment Partners Inc. lifted its holdings in Imago BioSciences by 108.3% during the first quarter. Ameritas Investment Partners Inc. now owns 1,556 shares of the company's stock valued at $30,000 after purchasing an additional 809 shares in the last quarter. Virtus ETF Advisers LLC purchased a new position in Imago BioSciences during the fourth quarter valued at $215,000. American International Group Inc. lifted its holdings in Imago BioSciences by 92.3% during the first quarter. American International Group Inc. now owns 9,964 shares of the company's stock valued at $192,000 after purchasing an additional 4,782 shares in the last quarter. Finally, MetLife Investment Management LLC purchased a new position in Imago BioSciences during the first quarter valued at $242,000. 99.50% of the stock is owned by hedge funds and other institutional investors.
其他大型投资者也改变了他们在该公司的头寸。纽约大都会人寿保险公司在第一季度收购了Imago BioSciences的一个新头寸,价值2.8万美元。Ameritas Investment Partners Inc.在第一季度增持了108.3%的Imago BioSciences股份。Ameritas Investment Partners Inc.现在持有1,556股该公司股票,价值3万美元,该公司在上个季度又购买了809股。Virtus ETF Advisers LLC在第四季度购买了Imago BioSciences的一个新头寸,价值21.5万美元。美国国际集团(American International Group Inc.)在第一季度增持了Imago BioSciences 92.3%的股份。美国国际集团(American International Group Inc.)在上个季度又购买了4,782股后,现在持有该公司9,964股股票,价值19.2万美元。最后,大都会人寿投资管理有限责任公司在第一季度收购了Imago BioSciences的一个新头寸,价值24.2万美元。99.50%的股票由对冲基金和其他机构投资者持有。
Insider Activity
内幕活动
In related news, insider Jennifer Peppe sold 5,598 shares of the firm's stock in a transaction dated Monday, August 15th. The shares were sold at an average price of $19.41, for a total transaction of $108,657.18. Following the completion of the sale, the insider now directly owns 148,809 shares in the company, valued at $2,888,382.69. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders sold 8,168 shares of company stock worth $155,402 over the last three months. Insiders own 14.90% of the company's stock.
在相关新闻中,内部人士珍妮弗·佩佩在8月15日星期一的一笔交易中出售了5598股该公司的股票。这些股票的平均价格为19.41美元,总成交额为108,657.18美元。出售完成后,这位内部人士现在直接拥有该公司148,809股,价值2,888,382.69美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的,该文件可以通过美国证券交易委员会网站获得。过去三个月,内部人士出售了8,168股公司股票,价值155,402美元。内部人士持有该公司14.90%的股份。
Analyst Ratings Changes
分析师评级发生变化
Imago BioSciences Stock Performance
Imago BioSciences股票表现
Shares of NASDAQ IMGO traded up $0.14 during mid-day trading on Friday, reaching $16.91. The company's stock had a trading volume of 86,921 shares, compared to its average volume of 105,353. The stock has a 50-day moving average of $16.38 and a two-hundred day moving average of $17.02. The stock has a market capitalization of $570.54 million, a P/E ratio of -9.50 and a beta of 2.48. Imago BioSciences, Inc. has a 1-year low of $11.56 and a 1-year high of $30.21.
周五午盘,纳斯达克IMGO的股价上涨了0.14美元,达到16.91美元。该公司股票的成交量为86,921股,而其平均成交量为105,353股。该股的50日移动均线切入位为16.38美元,200日移动均线切入位为17.02美元。该股市值为5.7054亿美元,市盈率为-9.50,贝塔系数为2.48。Imago BioSciences,Inc.的一年低点为11.56美元,一年高位为30.21美元。
Imago BioSciences Company Profile
Imago BioSciences公司简介
(Get Rating)
(获取评级)
Imago BioSciences, Inc, a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. Its lead product candidate is bomedemstat, which is in Phase II clinical trials for the treatment of myeloproliferative neoplasms chronic cancers of the bone marrow, such as myelofibrosis, essential thrombocythemia, and polycythemia vera.
临床阶段生物制药公司Imago BioSciences,Inc.发现和开发了针对赖氨酸特异性脱甲基酶1(LSD1)的小分子产品候选产品,LSD1是一种用于生产骨髓中血细胞的酶。它的主要候选产品是Bomedemstat,正在进行第二阶段临床试验,用于治疗骨髓增生性肿瘤和慢性骨髓癌,如骨髓纤维化、原发性血小板增多症和真性红细胞增多症。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on Imago BioSciences (IMGO)
- MarketBeat: Week in Review 9/5 – 9/9
- Prepare For A Record-Setting Quarter For Cyber Security Stocks
- The Auto Market Is Slowly Recovering, These Stocks May Outperform
- Is DocuSign On The Verge Of A Major Reversal?
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
- 免费获取StockNews.com关于Imago BioSciences(IMGO)的研究报告
- MarketBeat:回顾一周9/5-9/9
- 为网络安全股创纪录的季度做准备
- 汽车市场正在缓慢复苏,这些股票可能表现优异
- DocuSign是否即将发生重大逆转?
- 石油和天然气股票:投资可再生能源的安全途径
Want to see what other hedge funds are holding IMGO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Imago BioSciences, Inc. (NASDAQ:IMGO – Get Rating).
想看看其他对冲基金持有IMGO的股票吗?访问HoldingsChannel.com获取Imago BioSciences,Inc.(纳斯达克代码:IMGO-GET Rating)的最新13F申报文件和内幕交易信息。
Receive News & Ratings for Imago BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imago BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.
接受Imago生物科学日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Imago BioSciences和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧